Here's some local Houston startup news you may have missed. Photo by Zview/Getty Images

Houston startups across industries have been moving and shaking these past few weeks, and there's a chance you may have missed some of these Houston innovation stories.

In this roundup of short stories within Houston innovation, two Houston-based e-commerce startups announce big news, a tech company pitches abroad, and more.

Houston industrial e-commerce startup expands into the construction industry

Houston-based GoExpedi has expanded its business. Photo by Colt Melrose for GoExpedi

GoExpedi, an end-to-end digital supply chain and data analytics company with solutions within procurement and delivery of maintenance, repair, and operations products for heavy industries, announced it has expanded into the commercial construction space.

Builders partnering with GoExpedi now have access to more than 200,000 critical parts and supplies, according to a news release from the company.

"Access to needed tools and materials in construction is already a challenge in today's supply chain environment," says GoExpedi CEO Tim Neal in the release. "Expanding into commercial construction is a natural extension of our capabilities as we already provide significant operational and cost value with our digital platform across similar heavy sectors. We're quickly ramping up the number of construction groups we're working with, giving them a better way to plan for and order materials to help avoid costly building delays."

GoExpedi raised a $25 million series C round in 2020 and is deploying these funds as the company grows. Earlier this year, the startup opened a new industrial and energy MRO warehouse in Pittsburgh, Pennsylvania

UH business college snags prestigious grant

Dean​ Paul Pavlou leads the University of Houston's Bauer College of Business.

The University of Houston's C. T. Bauer College of Business is partnering with Texas A&M University and Temple University to develop and implement an energy risk tracking and alert system in Houston and San Antonio. The research project recently received $1.5 million in grant funding from the National Science Foundation. The grant is part of the Smart and Connected Communities program.

"Advanced Learning for Energy Risk Tracking" (ALERT) is designed to prevent and mitigate costly and potentially devastating electricity outages — such as the 2021 winter storm — according to a news release from UH. Bauer College Dean and Cullen Distinguished Chair Professor Paul A. Pavlou is one of co-investigators.

"If there is one positive outcome of the winter storm, it certainly created an awareness for many people that we need to invest more in intelligent systems that can minimize the huge costs and negative impacts that electricity outages can have on people and local communities," he says in the release. "The idea of this research is to create a data-driven system to reduce, predict, and mitigate costly power outages, especially in traditionally disadvantaged communities that usually suffer the most from power outages."

The ALERT system depends on data generated by utilities, city and county governments, school districts and others, enabling preemptive repairs and allowing officials to react more quickly in the event of unforeseen outages, per the release, and a test version of the resource may begin operating in San Antonio as soon as 2022, followed by a trial in Houston.

"It's a technologically very advanced solution, but the beauty of it is that we are working with local communities to acquire the data, to enhance the system and also feed the data back to the community to actually minimize the impact on the people who suffer most from power outages," Pavlou says in the release.

Houston health tech company receives new investment

Dan Purvis, CEO of Velentium

A Houston company has fresh funding. Photo courtesy of Velentium

Velentium has announced a growth recapitalization in partnership with Connecticut-based Great Point Partners. Houston-based Velentium is an engineering firm specializing in the design and manufacturing of therapeutic and diagnostic active medical devices, and GPP is a leading health care investment firm. The new investment allows Velentium to scale national operations.

"When Great Point reached out to us earlier this year, we were immediately impressed with their deep knowledge of our market and track record building businesses," says Dan Purvis, CEO of Velentium, in a news release. "We continue to build an organization that improves the lives of people and families by helping to bring transformative medical devices to market, and Great Point is uniquely positioned to enable us to do that at an even larger scale. Today, we are starting a new chapter and taking a crucial step in realizing our dream of having 1,000 families as part of our organization."

Velentium was created to advance the next breakthrough medical device technology — all within the same company. Innovators and inventors don't have to go through the processes — from cybersecurity to manufacturing — by themselves.

"Our dream from day one was to create a one-stop shop here in Houston where new startups with IP can come to us and know that start to finish they would have their commercial device ready for approval with the FDA and that we were going to handle everything," Purvis previously told InnovationMap.

With GPP's investment, Velentium is equipped to augment its end-to-end solutions and its nearshore and offshore manufacturing capabilities, per the release.

"Velentium has played a pivotal role in the development of groundbreaking neuromodulation devices that have led to important medical technology advancements," says GPP Managing Director Adam Dolder in the release. "We look forward to being partners with Dan, Tim and the entire team and helping them to achieve their goals for the company."

Houston startup tapped for European pitch competition

Jessica Reitmeier, is the co-founder of Pandata Tech. Photo courtesy of Pandata Tech

Houston-based Pandata Tech is one of 29 companies from around the globe competing in Scotland's Net Zero Technology Centre's Clean Energy Start-up Pitch Battle finals. Each featured company has a technology solution that can help accelerate the transition to a net zero energy industry, and 10 finalists will be selected to pitch at COP 26 UN Climate Change Conference in Glasgow, Scotland, on November 2, 2021.

"These start-ups are truly inspiring. Offering extraordinary innovation and ambition, all these teams are developing technologies that have significant potential to reduce greenhouse gas emissions," says Mark Anderson, TechX Director of Net Zero Technology Centre.

The Ion Houston nominated Pandata Tech to be part of the competition because of the startup's previous work in offshore energy and geothermal utility distribution.

"When we think about reducing C02 emissions by 50 percent or more by 2030 and the data required to meet that mark, it's simple — humans and algorithms need data they can trust," says Jessica Reitmeier, co-founder of Pandata.

Houston e-commerce services provider announces strategic partnership

Houston-based e-commerce software startup and Amazon competitor raises $25M in its series A

Cart.com has a new partner, which has increased access to tools for its clients. Photo via cart.com

Houston-based Cart.com, an end-to-end ecommerce services provider and Amazon competitor, announced a strategic partnership with Clearco, the world's largest ecommerce investor. With the new partnership, Cart.com's clients will receive access to Clearco's capital financing and Clearco's portfolio of over 5,500 companies will have access to Cart.com's end-to-end e-commerce platform.

"We're committed to making all aspects of running an ecommerce business streamlined and hassle-free — and that includes getting access to the capital needed to fuel growth," says Omair Tariq, Cart.com CEO, in a news release. "Through this partnership we're giving online sellers frictionless access to the resources they need to scale up, while allowing founders to stay laser-focused on serving their customers and building their brand."

The two companies share the mission to democratize ecommerce by delivering easier, more streamlined access to critical resources — including capital, services, and domain-specific information — which have previously only been available to companies like Amazon.

"Like Cart.com, we envision a world where founding a business is accessible to everyone, and where founders can access essential capital without having to jump through endless hoops," says Andrew D'Souza, Clearco CEO, in the release. "By partnering with Cart.com, Clearco companies will be able to access the platform's end-to-end ecommerce engine — including online store technology, integrated fulfillment services, and customer service support — to scale their ecommerce growth."

This week's roundup of Houston innovators includes Dan Purvis of Velentium, Tony Sanchez of OneNexus Environmental, and Kevin Doffing of Energy Capital of the Future. Courtesy photos

3 Houston innovators to know this week

who's who

Keep reading...Show less
Dan Purvis, CEO and founder of Velentium, is leading his growing company with culture in mind. Photo courtesy of Velentium

Local tech exec expands med device company into oil and gas in a 'uniquely Houston' way

HOUSTON INNOVATORS PODCAST EPISODE 90

When asked about founding his company, the first thing Dan Purvis wants to talk about is the culture.

"The technology of today and the technology of 24 months from now will be very different," Purvis, CEO and founder of Houston-based Velentium, says on this week's episode of the Houston Innovators Podcast. "Being culture-forward allows us to make sure that the people we have on staff are able to flex with the industry."

Velentium was created to advance the next breakthrough medical device technology — all within the same company. Innovators and inventors don't have to go through the processes — from cybersecurity to manufacturing — by themselves.

"Our dream from day one was to create a one-stop shop here in Houston where new startups with IP can come to us and know that start to finish they would have their commercial device ready for approval with the FDA and that we were going to handle everything," Purvis explains.

These days, cybersecurity is top of mind for Velentium, as the technology Purvis and his team are working with include life and death situations. While IT and other software security is important, protecting patients using new medical devices is paramount.

"If you have a dog in your backyard and you have one hole in your fence, you're dog is going to get out," Purvis says."You can't have any holes in that fence. … Our design allows for that protection."

Following an acquisition of Magnolia, Texas-based Oasis Testing, a designer of automated test systems for the energy and manufacturing industries in January, Velentium has expanded to also work in oil and gas technology development. While completely different fields, Velentium says the entrance into this energy tech market has been smooth sailing.

"We really find that both sides of the company cross pollinate quite a bit, and I think that's something that's uniquely Houston," Purvis says.

He shares more about the expansion and how his company continues to grow on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

A new medical device created in Houston is revolutionizing opioid withdrawal treatment. Photo via sparkbiomedical.com

Houston med-tech companies partner on wearable device for opioid withdrawal

treating addiction

Houston-based Spark Biomedical has created a revolutionary wearable device that provides unprecedented levels of opioid withdrawal relief.

The device known as the Sparrow Therapy System is worn over the ear for five to seven days and sends mild electrical signals to trigger cranial nerves that sit near the skin's surface.

Once activated, the nerves release endorphins that the body has stopped producing on its own during opioid use. The endorphins satisfy the opioid receptors and in turn reduce or prevent the intense symptoms that often come along with opioid withdrawal. According to Spark BioMed CEO Daniel Powell, the technology also helps patients better control their "flight or fight mechanisms," allowing them to make clearer, more logical decisions as they come off of the drug.

"If you ask 100 people who've gone through opioid withdrawal, I would bet 99 of them will tell you they thought they were going to die," Powell says. "Giving them the ability to manage that is huge. It's the first step towards addiction recovery. It's not solving the addiction, but it is an absolute barrier to move forward."

The product was approved by the FDA in January of 2020, after clinical trials showed that the Sparrow could meaningfully reduce withdrawal symptoms in the first hour of use. According to Powell, roughly a third of patients in the trial were completely out of withdrawal and patients' Clinical Opioid Withdrawal Scales scores reduced by more than 53 percent across the board.

Spark, which won Venture Houston's inaugural pitch competition earlier this year, partnered with Houston-based Velentium (which also happened to grow 93 percent last year after partnering with General Motors on Project V) to bring the product from concept to commercial physician prescribed product. "We needed a more sophisticated design house to help us finish it," Powell says.

The up-and-comers were connected through one of Spark's investors. Powell, in a previous career, had also sold a neurostimulator that Velentium CTO Randy Armstrong had invented.

"You're seeing more and more Houston centric medical innovation than we've ever seen before," says Velentium CEO Dan Purvis. "And the cool thing about that is there ends up being a camaraderie amongst entrepreneurs, medical researchers and scientists."

And though the release of Sparrow marks a huge milestone, neither Spark of Velentium are stopping there. Moving forward, Spark aims to conduct a massive study on how a similar technology, dubbed the Roo, can aid infants born to opioid-dependent mothers wean from the drug.

The company also aims to create a next generation Sparrow with the help of Velentium, and will look at long-term uses of the product. Powell says that Spark will look to determine if the product can prevent relapses and help to cure addiction when worn daily or regularly.

"Our big, crazy, ambitious goal is can we actually help people recover from addiction," Powell says. "We're really not addressing psychology, that's going to be in cognitive behavioral therapy. But if we can remove the neurological results of drug use, we think we can make at least start to stack the deck in the favor of the patient versus having the deck stacked completely against them all the time."

This week's roundup of Houston innovators includes Niloufar Molavi of Central Houston Inc., Dan Purvis of Velentium, and Chris Staffel of Goose Capital. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In the week's roundup of Houston innovators to know, I'm introducing you to three innovators — each either new to their role or with a bit of acquistion news.

Niloufar Molavi, board chair at Central Houston Inc.

Niloufar Molavi will lead Central Houston Inc.'s board this year — and she's got fostering innovation on her to-do list. Photo courtesy of CHI

Last week, Nilofar Molavi assumed the role of board chair for Central Houston. She leads PwC's Global energy practice and has served on the CHI board since 2011 and chairs the organization's innovation committee. CHI was among the partners behind the Downtown Launchpad, a 17,000-square-foot innovation hub, which had its grand opening last fall.

"With the fall 2020 opening of Downtown Launchpad, we have deepened our investment in innovation, which we hope will garner long-term results and economic vitality for downtown as well as the Houston region at large," she continues. "We look forward to developing bridge programs with area universities and organizations and leveraging existing resources to bring more high-tech prospects to our central city." Read more.

Dan Purvis, CEO of Velentium

A Houston company has made a strategic acquisition. Photo courtesy of Velentium

Houston-based Velentium, which specializes in the design and manufacturing of medical devices announced that it has acquired Texas company Oasis Testing, a designer of automated test systems for the energy and manufacturing industries.

"Despite the immense challenges facing the business community in 2020, last year was a monumental year of growth for our firm, and we're pleased to start 2021 building upon our world-class team of technical experts," says Dan Purvis, CEO of Velentium, in a news release. "Oasis Testing has been a trusted partner for the last five years and shares in our commitment to solving clients' most complex challenges to change lives for a better world. We're incredibly excited to welcome them to the Velentium family and expand our business more deeply into energy and manufacturing."

Purvis will lead the new combined company as CEO. Read more.

Chris Staffel, managing director at Goose Capital

Goose Capital recently named its new managing director. Photo courtesy of Chris Staffel

Houston-based investment group Goose Capital Inc. named Chris Staffel as managing director — along with Jeff Smisek as the firm's president and Jay Collins as chair of the board of directors.

A serial entrepreneur and investor in over 30 startups, Staffel joins Goose to lead day-to-day operations and drive new investment opportunities.

"It is an honor to join the team at Goose Capital and work alongside experienced industry leaders," Staffel says in the release. "I look forward to leveraging my entrepreneurial experience to help the start-ups in which we invest, while strategically identifying early stage investment opportunities." Read more.

Dan Purvis, CEO of Velentium, will lead the new combined company. Photo courtesy of Veletium

Houston-area medical device engineering firm acquires Texas company

M&A

A engineering firm based in Katy has made a strategic acquisition of a Magnolia, Texas-based company to start of the new year.

Velentium, which specializes in the design and manufacturing of medical devices announced that it has acquired Oasis Testing, a designer of automated test systems for the energy and manufacturing industries.

"Despite the immense challenges facing the business community in 2020, last year was a monumental year of growth for our firm, and we're pleased to start 2021 building upon our world-class team of technical experts," says Dan Purvis, CEO of Velentium, in a news release. "Oasis Testing has been a trusted partner for the last five years and shares in our commitment to solving clients' most complex challenges to change lives for a better world. We're incredibly excited to welcome them to the Velentium family and expand our business more deeply into energy and manufacturing."

The companies will operate under the Velentium name, and Demetri White, co-founder at Oasis Testing, will assume the role of senior program manager to focus on "growing the testing business, serving the oil and gas industry's need for high-pressure high-temperature test, as well as testing in the medical device sector," according to the release.

"We admire and share Velentium's approach to client service, company culture, and results-focused business strategy, and quickly recognized this would be an excellent fit for our team," says White in the. "From our years of partnership, we know that Oasis' expertise in servicing the energy and manufacturing sectors goes hand-in-hand with their ability to provide innovative and world class solutions. Together, we will leverage knowledge across industries to bring mechanical, electrical and software-based solutions that benefit our client base."

The new company will have expanded abilities and will be increasing its production space and headcount as it continues to place an emphasis on its testing and manufacturing capabilities. The added resources for automation and the combined team will lead to dramatic reductions in product test times and increased test system utilization.

Earlier this year, Velentium played a key role in mobilizing thousands of ventilators in the United States at a time when the pandemic and the uncertainty around it was surmounting around the country.

The company's long-time clients Ventec Life Systems, a manufacturer of ventilators based in Washington, said they could increase production of their much-needed ventilators five-fold if they only had the right resources and partners. Velentium first aimed to help the small factory double or triple their production, and later General Motors jumped in to help grow the initiative.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.